Classification of PR-positive and PR-negative subtypes in ER-positive and HER2-negative breast cancers based on pathway scores

PURPOSE: PR loss in ER+/HER2- breast cancer indicates worse prognosis and insensitivity to anti-estrogen therapy, while the mechanisms of PR loss in ER+/HER2- breast cancer remain unrevealed. METHODS: In this study, ER+/PR+/HER2- and ER+/PR-/HER2- breast cancer cases from TCGA were used. 1387 pathwa...

Descripción completa

Detalles Bibliográficos
Autores principales: Hu, Taobo, Chen, Yan, Liu, Yiqiang, Zhang, Danhua, Pan, Jiankang, Long, Mengping
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8141178/
https://www.ncbi.nlm.nih.gov/pubmed/34022815
http://dx.doi.org/10.1186/s12874-021-01297-8
_version_ 1783696312667996160
author Hu, Taobo
Chen, Yan
Liu, Yiqiang
Zhang, Danhua
Pan, Jiankang
Long, Mengping
author_facet Hu, Taobo
Chen, Yan
Liu, Yiqiang
Zhang, Danhua
Pan, Jiankang
Long, Mengping
author_sort Hu, Taobo
collection PubMed
description PURPOSE: PR loss in ER+/HER2- breast cancer indicates worse prognosis and insensitivity to anti-estrogen therapy, while the mechanisms of PR loss in ER+/HER2- breast cancer remain unrevealed. METHODS: In this study, ER+/PR+/HER2- and ER+/PR-/HER2- breast cancer cases from TCGA were used. 1387 pathways were analyzed and used as variables for classifying the two groups with LASSO regression. RESULTS: ER+/PR+/HER2- and ER+/PR-/HER2- breast cancer groups can be classified by a combination of 13 pathways using their activity score. Among the 13 pathways, those involving growth factors and ion-channel transporters were most significant in the distinction, followed by pathways involving immune modulation and cell metabolism. Two growth factor pathways, EGF and IGF-1, were deferentially regulated in ER+/PR+/HER2- and ER+/PR-/HER2- groups. CONCLUSIONS: In conclusion, this study indicated in ER+/HER2- breast cancers the various status of PR expression can be an indication of molecular variation, particularly for the growth factor pathway activation. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12874-021-01297-8.
format Online
Article
Text
id pubmed-8141178
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-81411782021-05-25 Classification of PR-positive and PR-negative subtypes in ER-positive and HER2-negative breast cancers based on pathway scores Hu, Taobo Chen, Yan Liu, Yiqiang Zhang, Danhua Pan, Jiankang Long, Mengping BMC Med Res Methodol Research PURPOSE: PR loss in ER+/HER2- breast cancer indicates worse prognosis and insensitivity to anti-estrogen therapy, while the mechanisms of PR loss in ER+/HER2- breast cancer remain unrevealed. METHODS: In this study, ER+/PR+/HER2- and ER+/PR-/HER2- breast cancer cases from TCGA were used. 1387 pathways were analyzed and used as variables for classifying the two groups with LASSO regression. RESULTS: ER+/PR+/HER2- and ER+/PR-/HER2- breast cancer groups can be classified by a combination of 13 pathways using their activity score. Among the 13 pathways, those involving growth factors and ion-channel transporters were most significant in the distinction, followed by pathways involving immune modulation and cell metabolism. Two growth factor pathways, EGF and IGF-1, were deferentially regulated in ER+/PR+/HER2- and ER+/PR-/HER2- groups. CONCLUSIONS: In conclusion, this study indicated in ER+/HER2- breast cancers the various status of PR expression can be an indication of molecular variation, particularly for the growth factor pathway activation. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12874-021-01297-8. BioMed Central 2021-05-22 /pmc/articles/PMC8141178/ /pubmed/34022815 http://dx.doi.org/10.1186/s12874-021-01297-8 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Hu, Taobo
Chen, Yan
Liu, Yiqiang
Zhang, Danhua
Pan, Jiankang
Long, Mengping
Classification of PR-positive and PR-negative subtypes in ER-positive and HER2-negative breast cancers based on pathway scores
title Classification of PR-positive and PR-negative subtypes in ER-positive and HER2-negative breast cancers based on pathway scores
title_full Classification of PR-positive and PR-negative subtypes in ER-positive and HER2-negative breast cancers based on pathway scores
title_fullStr Classification of PR-positive and PR-negative subtypes in ER-positive and HER2-negative breast cancers based on pathway scores
title_full_unstemmed Classification of PR-positive and PR-negative subtypes in ER-positive and HER2-negative breast cancers based on pathway scores
title_short Classification of PR-positive and PR-negative subtypes in ER-positive and HER2-negative breast cancers based on pathway scores
title_sort classification of pr-positive and pr-negative subtypes in er-positive and her2-negative breast cancers based on pathway scores
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8141178/
https://www.ncbi.nlm.nih.gov/pubmed/34022815
http://dx.doi.org/10.1186/s12874-021-01297-8
work_keys_str_mv AT hutaobo classificationofprpositiveandprnegativesubtypesinerpositiveandher2negativebreastcancersbasedonpathwayscores
AT chenyan classificationofprpositiveandprnegativesubtypesinerpositiveandher2negativebreastcancersbasedonpathwayscores
AT liuyiqiang classificationofprpositiveandprnegativesubtypesinerpositiveandher2negativebreastcancersbasedonpathwayscores
AT zhangdanhua classificationofprpositiveandprnegativesubtypesinerpositiveandher2negativebreastcancersbasedonpathwayscores
AT panjiankang classificationofprpositiveandprnegativesubtypesinerpositiveandher2negativebreastcancersbasedonpathwayscores
AT longmengping classificationofprpositiveandprnegativesubtypesinerpositiveandher2negativebreastcancersbasedonpathwayscores

Ejemplares similares